Squamous Cell Carcinoma Of The Head And Neck – Unmet Need – Detailed, Expanded Analysis: Squamous Cell Carcinoma Of The Head And Neck (US/EU) 2022
The angiogenesis inhibitor Erbitux, in combination with platinum-based therapy and 5-fluorouracil (5-FU), was the standard treatment option for all squamous cell carcinoma of the head and neck (SCCHN) patients in the first-line recurrent or metastatic setting. The approval of immune checkpoint inhibitors—Keytruda (Merck & Co.) and Opdivo (Bristol-Myers Squibb)—in the first-line setting over the last decade has changed the treatment paradigm for recurrent or metastatic SCCHN patients as monotherapy and/or in combination with platinum + 5-FU. However, there is a strong need for effective therapies in this patient setting. This report provides a detailed analysis of the factors that influence medical oncologists' prescribing decisions and reviews the unmet needs that novel therapies should confront.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in medical oncologists’ prescribing decisions for non-nasopharyngeal SCCHN?
- How do current therapies, such as immune checkpoint inhibitors, perform on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need and hidden opportunity that drug developers could leverage in the treatment of non-nasopharyngeal SCCHN?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical target product profile for non-nasopharyngeal SCCHN?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 33 European medical oncologists fielded in December 2021
Key companies: Merck & Co., Bristol Myers Squibb, Eli Lilly
Key drugs: Erbitux, Keytruda, Opdivo
Table of contents
- Squamous Cell Carcinoma Of The Head And Neck - Unmet Need - Detailed, Expanded Analysis: Squamous Cell Carcinoma Of The Head And Neck (US/EU) 2022
- Executive summary
- Unmet Need - Recurrent or Metastatic Non-Nasopharyngeal SCCHN - Executive Summary - March 2021
- Introduction
- Overview
- Methodology
- Rationale for treatment drivers and goals selection
- Rationale for drug selection
- Products / regimens for recurrent or metastatic non-nasopharyngeal SCCHN and rationale for drug selection
- Treatment drivers and goals
- Key findings: attribute importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Medical Oncologists' Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN
- Importance of efficacy attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Importance of safety and tolerability attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Importance of safety and tolerability attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
- Importance of convenience of administration attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Overall Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Mean overall performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN: United States and Europe
- Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select efficacy attributes: United States
- Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select efficacy attributes: Europe
- Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Safety and Tolerability Attributes: United States
- Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select safety and tolerability attributes: Europe
- Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Convenience of Administration Attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in recurrent or metastatic non-nasopharyngeal SCCHN
- Surveyed Medical Oncologistsu2019 Satisfaction with the Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Key findings: unmet need in recurrent or metastatic non-nasopharyngeal SCCHN and related indications
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Recurrent or Metastatic Non-Nasopharyngeal SCCHN and Related Indications: United States
- Surveyed medical oncologists' ascribed level of unmet need in recurrent or metastatic non-nasopharyngeal SCCHN and related indications: Europe
- Opportunity analysis
- Areas of opportunity in the recurrent or metastatic non-nasopharyngeal SCCHN market and emerging therapy insights
- Opportunity: a novel therapy offering a substantial overall survival benefit
- Opportunity: a novel therapy offering an improved and durable response
- Opportunity: a novel therapy offering an improved quality of life
- Areas of opportunity in the recurrent or metastatic non-nasopharyngeal SCCHN market and emerging therapy insights
- Target product profiles
- Assessing drug development opportunities
- Target product profile methodology
- Attributes and attribute levels
- Attribute importance and part-worth utilities
- First-line recurrent or metastatic non-nasopharyngeal SCCHN target product profile: attribute importance
- Median overall survival (months)
- Median progression-free survival (months)
- Objective response rate (% of patients)
- Incidence of grade 3/4 hematological toxicities (% of patients)
- Incidence of grade 3/5 immune-mediated adverse events (% of patients)
- Quality of life (Global Health Status / QLQ-30 Score)
- Price per 21-day cycle
- Conjoint analysis-based simulation of a market scenario
- First-line recurrent or metastatic non-nasopharyngeal SCCHN market simulation: share of preference of target product profiles Included in the market scenario
- First-line recurrent or metastatic non-nasopharyngeal SCCHN market simulation: likelihood to prescribe target product profiles included in the market scenario
- First-line recurrent or metastatic non-nasopharyngeal SCCHN market simulation: target product profiles included in the market scenario
- Appendix
- Bibliography
- Executive summary
Divisha Jain, M.S. (Pharm)., is a research associate on the Oncology team at Clarivate. She works on the Oncology Clinical Trial Monitor. Previously, Ms. Jain was a research scientist at Dr. Reddy’s Laboratories. She obtained her master’s degree in pharmaceutics from the National Institute of Pharmaceutical Education and Research in Mohali, India, and her bachelor’s degree from Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research in Pune, India.
Rajashri Lella, M.Pharm., is a research associate on the Oncology team at Clarivate. She performs secondary market research, which includes patent research and pricing for major pharmaceutical markets covering multiple oncology indications. She previously worked on the Oncology Clinical Trial Monitor. Ms. Lella completed a master’s degree in pharmaceutical quality assurance at Manipal Academy of Higher Education in India.